# Eris Lifesciences Ltd (ERIS)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1343.8
Day Change: -3.04%
52W High: ₹1910
52W Low: ₹1200
Market Cap: ₹18,641 Cr

## Valuation
P/E: 42.67
P/B: 5.93
EPS: ₹31.53
Book Value: ₹226.84
Dividend Yield: 0%

## Returns
1Y Return: -15.95%

## Profitability
ROE: 0%
ROCE: 13.83%
Debt/Equity: 0.68
Revenue Growth: 10.9%
Profit Growth: 19.1%
EBITDA Margin: 39.61%
Operating Margin: 26.38%

## About
Eris Lifesciences Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Eris Lifesciences Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Quarterly Report: Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-24T20:00:07.443Z
Price History Updated: 2026-05-18T22:58:18.282Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:18.282Z
Quant Updated: 2026-05-18T22:58:18.282Z
Sentiment Updated: 2026-05-18T22:58:18.282Z
Financials Status: current
Financials Updated: 2026-05-18T09:30:39.570Z
Financials Last Attempt: 2026-05-18T09:30:39.570Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹509 Cr
Operating Profit: ₹95 Cr (OPM 19%)
Net Profit: ₹71 Cr
Tax: ₹98 Cr

## Annual P&L History
Mar 2015: Rev ₹509Cr | PAT ₹71Cr | OPM 19%
Mar 2016: Rev ₹546Cr | PAT ₹89Cr | OPM 22%
Mar 2017: Rev ₹597Cr | PAT ₹135Cr | OPM 29%

## Balance Sheet (Mar 2015)
Total Assets: ₹271 Cr
Total Liabilities: ₹271 Cr
Borrowings: ₹1 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Amit Indubhushan Bakshi, Chairman & MD
- Sachin  Shah, Chief Financial Officer
- Krishnakumar  Vaidyanathan, Executive Director & COO
- Milind  Talegaonkar, Compliance Officer & Company Secretary
- Gagan  Atreja, President of Sales & Marketing

---
Source: rupiya.io/stocks/eris
Disclaimer: For research and education only. Not investment advice.